Aggregator

Our recommendations for giving in 2021

2 years 4 months ago

You can have a remarkable impact by supporting cost-effective, evidence-based charities.

Just looking at the approximately $100 million GiveWell had discretion to grant in 2020—a subset of all the money we directed to the charities we recommend—the impact of our donors is impressive. We estimate these grants will:

  • Save more than 24,000 lives
  • Treat over 6 million children with a full course of antimalarial medication
  • Provide vitamin A supplementation to over 8.6 million children
  • Deliver over 4.4 million long-lasting insecticide-treated nets (LLINs) to protect against malaria
  • Vaccinate 118,000 children
  • Treat over 11.4 million children for parasitic worms

Read More

The post Our recommendations for giving in 2021 appeared first on The GiveWell Blog.

Ben Bateman

Our recommendations for giving in 2021

2 years 4 months ago

You can have a remarkable impact by supporting cost-effective, evidence-based charities.

Just looking at the approximately $100 million GiveWell had discretion to grant in 2020—a subset of all the money we directed to the charities we recommend—the impact of our donors is impressive. We estimate these grants will:

  • Save more than 24,000 lives
  • Treat over 6 million children with a full course of antimalarial medication
  • Provide vitamin A supplementation to over 8.6 million children
  • Deliver over 4.4 million long-lasting insecticide-treated nets (LLINs) to protect against malaria
  • Vaccinate 118,000 children
  • Treat over 11.4 million children for parasitic worms

Read More

The post Our recommendations for giving in 2021 appeared first on The GiveWell Blog.

Ben Bateman

Our recommendations for giving in 2021

2 years 4 months ago

You can have a remarkable impact by supporting cost-effective, evidence-based charities.

Just looking at the approximately $100 million GiveWell had discretion to grant in 2020—a subset of all the money we directed to the charities we recommend—the impact of our donors is impressive. We estimate these grants will:

  • Save more than 24,000 lives
  • Treat over 6 million children with a full course of antimalarial medication
  • Provide vitamin A supplementation to over 8.6 million children
  • Deliver over 4.4 million long-lasting insecticide-treated nets (LLINs) to protect against malaria
  • Vaccinate 118,000 children
  • Treat over 11.4 million children for parasitic worms

Read More

The post Our recommendations for giving in 2021 appeared first on The GiveWell Blog.

Ben Bateman

Our recommendations for giving in 2021

2 years 4 months ago

You can have a remarkable impact by supporting cost-effective, evidence-based charities.

Just looking at the approximately $100 million GiveWell had discretion to grant in 2020—a subset of all the money we directed to the charities we recommend—the impact of our donors is impressive. We estimate these grants will:

  • Save more than 24,000 lives
  • Treat over 6 million children with a full course of antimalarial medication
  • Provide vitamin A supplementation to over 8.6 million children
  • Deliver over 4.4 million long-lasting insecticide-treated nets (LLINs) to protect against malaria
  • Vaccinate 118,000 children
  • Treat over 11.4 million children for parasitic worms

Read More

The post Our recommendations for giving in 2021 appeared first on The GiveWell Blog.

Ben Bateman

We aim to cost-effectively direct around $1 billion annually by 2025

2 years 4 months ago

A little over a decade ago in 2010, GiveWell directed around $1.5 million to the charities we recommended. In 2021, we expect we’ll raise at least $500 million, and may raise as much as $560 million or more.

We never anticipated that we’d grow this large this quickly. We’ve seen rapid growth from donors of all sizes, the most recent of which is a commitment of $300 million from Open Philanthropy.

While this growth comes with challenges—we’re working hard to hire enough researchers—it’s a testament to our donors' trust in us and enthusiasm for our mission.

But these big numbers are relatively small in the long-term scope of what GiveWell hopes to achieve. We believe there are billions of dollars' worth of annual cost-effective giving opportunities that we have yet to identify.

Read More

The post We aim to cost-effectively direct around $1 billion annually by 2025 appeared first on The GiveWell Blog.

Ben Bateman

We aim to cost-effectively direct around $1 billion annually by 2025

2 years 4 months ago

A little over a decade ago in 2010, GiveWell directed around $1.5 million to the charities we recommended. In 2021, we expect we’ll raise at least $500 million, and may raise as much as $560 million or more.

We never anticipated that we’d grow this large this quickly. We’ve seen rapid growth from donors of all sizes, the most recent of which is a commitment of $300 million from Open Philanthropy.

While this growth comes with challenges—we’re working hard to hire enough researchers—it’s a testament to our donors' trust in us and enthusiasm for our mission.

But these big numbers are relatively small in the long-term scope of what GiveWell hopes to achieve. We believe there are billions of dollars' worth of annual cost-effective giving opportunities that we have yet to identify.

Read More

The post We aim to cost-effectively direct around $1 billion annually by 2025 appeared first on The GiveWell Blog.

Ben Bateman

Why malnutrition treatment is one of our top research priorities

2 years 5 months ago

We believe malnutrition is a very promising area for charitable funding in the future. In 2021, we directed nearly $30 million to two organizations—The Alliance for International Medical Action (ALIMA) and International Rescue Committee (IRC)—working on malnutrition, and we expect to direct more funding to malnutrition programs in the future. (We have published a write-up about one of these grants here and will publish write-ups about the other grants in the near future.) To give a sense of what we expect, we would not be surprised if GiveWell directs as much funding to malnutrition in the future as we have to malaria programs in recent years.

Read More

The post Why malnutrition treatment is one of our top research priorities appeared first on The GiveWell Blog.

Marinella Capriati

Why malnutrition treatment is one of our top research priorities

2 years 5 months ago

We believe malnutrition is a very promising area for charitable funding in the future. In 2021, we directed nearly $30 million to two organizations—The Alliance for International Medical Action (ALIMA) and International Rescue Committee (IRC)—working on malnutrition, and we expect to direct more funding to malnutrition programs in the future. (We have published a write-up about one of these grants here and will publish write-ups about the other grants in the near future.) To give a sense of what we expect, we would not be surprised if GiveWell directs as much funding to malnutrition in the future as we have to malaria programs in recent years.

Read More

The post Why malnutrition treatment is one of our top research priorities appeared first on The GiveWell Blog.

Marinella Capriati

GiveWell’s money moved in 2020

2 years 5 months ago

2020 was another year of tremendous growth. GiveWell donors contributed over $240 million to our recommended charities (our “2020 money moved”), a 60% increase from the approximately $150 million we directed in 2019. This is part of an exciting, long-term trend. Just a decade ago, in 2010, GiveWell’s total money moved was $1.5 million.[1]

We believe these donations will save tens of thousands of lives and benefit many others. This incredible impact would not be possible without the continued support and generosity of our donors. While our research enables us to identify and recommend highly cost-effective giving opportunities, our donors are responsible for turning those recommendations into real change for some of the poorest individuals in the world.

This post lays out highlights from our final 2020 money moved report and shares more details about how donors gave to GiveWell’s recommended charities in 2020.[2]

Summary of influence: In 2020, GiveWell influenced charitable giving in several ways. The following table summarizes our understanding of this influence.

Headline money moved: In 2020, we confidently tracked $244 million in money moved to our recommended charities, and via our GiveWell Incubation Grants program. This amount, which we call “headline money moved,” only counts donations that we are confident were influenced by our recommendations. This includes the grants we make through the Maximum Impact Fund. See Appendix 1 of our 2020 metrics report for additional details on how we calculate our money moved.

We also estimate that we are responsible for an additional $3 million in donations, but we are unable to attribute these donations directly to GiveWell. Because we are more uncertain about this influence, we do not include this amount in our “headline money moved” figure but include it in our “best guess of total money directed to charities” figure. [3]

The chart below shows the breakdown of our headline money moved into the following categories: grants that Open Philanthropy made to our recommended charities, donations from other donors to our recommended charities, and Incubation Grants. Please note that Open Philanthropy support (marked in gray) does not include funding it provided for GiveWell Incubation Grants, which are shown separately in purple. [4]

Money moved by charity (excluding Incubation Grants): Our nine top charities received the majority of our money moved. Our nine standout charities received a total of $2.2 million. Note that as of October 2021, we have discontinued the standout charity designation. [5]

Money moved by program (excluding Incubation Grants): Our recommended charities implement a variety of health and poverty alleviation programs. But some charities work on the same type of program. For example, we recommend four charities for their programs that support treatments for parasitic worm infections (deworming programs), and two charities for their programs to prevent malaria (Malaria Consortium’s seasonal malaria chemoprevention program and the Against Malaria Foundation). Here, we look at the breakdown of money moved by program type.

The majority of our money moved, including donations to our Maximum Impact Fund, was directed to malaria prevention programs—followed by unconditional cash transfers, conditional cash transfers to promote vaccination, deworming, and vitamin A supplementation. Other programs each received less than 1% of our total money moved.

Money moved by size of donor: We also analyze our money moved by the amount that different donors give, which we categorize into six different “size buckets” (see the chart below, which excludes funding from Open Philanthropy).

A caveat: Our analysis of money moved by donor size is incomplete because for approximately 39% of donations (excluding Open Philanthropy), we do not have data disaggregated by individual donor. Among the donations we can attribute to individual donors, the amount of money given increased across all donor size categories compared to 2019. Details are available in the full report.


Donations supporting GiveWell’s operations: GiveWell raised $43.6 million in unrestricted funding in 2020, compared to $19 million in 2019. Donors who gave over $100,000, including Open Philanthropy, contributed around 84% of GiveWell’s unrestricted funding in 2020. GiveWell’s total operating expenses in 2020 were $8.5 million.

We have only retained a portion of our unrestricted 2020 revenue for operating costs, and will be reallocating the remainder to discretionary grantmaking. [6]

For more detail, see our full metrics report (PDF).

References

Footnotes for this post may be found here.

The post GiveWell’s money moved in 2020 appeared first on The GiveWell Blog.

Robin Dey

GiveWell’s money moved in 2020

2 years 5 months ago

2020 was another year of tremendous growth. GiveWell donors contributed over $240 million to our recommended charities (our "2020 money moved"), a 60% increase from the approximately $150 million we directed in 2019. This is part of an exciting, long-term trend. Just a decade ago, in 2010, GiveWell’s total money moved was $1.5 million.

We believe these donations will save tens of thousands of lives and benefit many others. This incredible impact would not be possible without the continued support and generosity of our donors. While our research enables us to identify and recommend highly cost-effective giving opportunities, our donors are responsible for turning those recommendations into real change for some of the poorest individuals in the world.

Read More

The post GiveWell’s money moved in 2020 appeared first on The GiveWell Blog.

Robin Dey

GiveWell’s money moved in 2020

2 years 5 months ago

2020 was another year of tremendous growth. GiveWell donors contributed over $240 million to our recommended charities (our “2020 money moved”), a 60% increase from the approximately $150 million we directed in 2019. This is part of an exciting, long-term trend. Just a decade ago, in 2010, GiveWell’s total money moved was $1.5 million.[1]

We believe these donations will save tens of thousands of lives and benefit many others. This incredible impact would not be possible without the continued support and generosity of our donors. While our research enables us to identify and recommend highly cost-effective giving opportunities, our donors are responsible for turning those recommendations into real change for some of the poorest individuals in the world.

This post lays out highlights from our final 2020 money moved report and shares more details about how donors gave to GiveWell’s recommended charities in 2020.[2]

Summary of influence: In 2020, GiveWell influenced charitable giving in several ways. The following table summarizes our understanding of this influence.

Headline money moved: In 2020, we confidently tracked $244 million in money moved to our recommended charities, and via our GiveWell Incubation Grants program. This amount, which we call “headline money moved,” only counts donations that we are confident were influenced by our recommendations. This includes the grants we make through the Maximum Impact Fund. See Appendix 1 of our 2020 metrics report for additional details on how we calculate our money moved.

We also estimate that we are responsible for an additional $3 million in donations, but we are unable to attribute these donations directly to GiveWell. Because we are more uncertain about this influence, we do not include this amount in our “headline money moved” figure but include it in our “best guess of total money directed to charities” figure. [3]

The chart below shows the breakdown of our headline money moved into the following categories: grants that Open Philanthropy made to our recommended charities, donations from other donors to our recommended charities, and Incubation Grants. Please note that Open Philanthropy support (marked in gray) does not include funding it provided for GiveWell Incubation Grants, which are shown separately in purple. [4]

Money moved by charity (excluding Incubation Grants): Our nine top charities received the majority of our money moved. Our nine standout charities received a total of $2.2 million. Note that as of October 2021, we have discontinued the standout charity designation. [5]

Money moved by program (excluding Incubation Grants): Our recommended charities implement a variety of health and poverty alleviation programs. But some charities work on the same type of program. For example, we recommend four charities for their programs that support treatments for parasitic worm infections (deworming programs), and two charities for their programs to prevent malaria (Malaria Consortium’s seasonal malaria chemoprevention program and the Against Malaria Foundation). Here, we look at the breakdown of money moved by program type.

The majority of our money moved, including donations to our Maximum Impact Fund, was directed to malaria prevention programs—followed by unconditional cash transfers, conditional cash transfers to promote vaccination, deworming, and vitamin A supplementation. Other programs each received less than 1% of our total money moved.

Money moved by size of donor: We also analyze our money moved by the amount that different donors give, which we categorize into six different “size buckets” (see the chart below, which excludes funding from Open Philanthropy).

A caveat: Our analysis of money moved by donor size is incomplete because for approximately 39% of donations (excluding Open Philanthropy), we do not have data disaggregated by individual donor. Among the donations we can attribute to individual donors, the amount of money given increased across all donor size categories compared to 2019. Details are available in the full report.


Donations supporting GiveWell’s operations: GiveWell raised $43.6 million in unrestricted funding in 2020, compared to $19 million in 2019. Donors who gave over $100,000, including Open Philanthropy, contributed around 84% of GiveWell’s unrestricted funding in 2020. GiveWell’s total operating expenses in 2020 were $8.5 million.

We have only retained a portion of our unrestricted 2020 revenue for operating costs, and will be reallocating the remainder to discretionary grantmaking. [6]

For more detail, see our full metrics report (PDF).

References

Footnotes for this post may be found here.

The post GiveWell’s money moved in 2020 appeared first on The GiveWell Blog.

Robin Dey

Initial thoughts on malaria vaccine approval

2 years 6 months ago

The World Health Organization (WHO) recently recommended the widespread use of the malaria vaccine RTS,S/AS011We’ll use “RTS,S” as shorthand in this post. jQuery('#footnote_plugin_tooltip_13408_1_1').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_1', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); for children. It provides an additional, effective tool to fight malaria. This is great news!

We’ve been following this vaccine’s development for years and, in the last few months, have been speaking with organizations involved in its development and potential wider rollout.

Our work on RTS,S (and other malaria vaccines) is ongoing, and we might significantly update our views in the near future. But because we’ve been following its progress, we’re sharing some initial thoughts.

In brief
  • This vaccine is a promising addition to the set of tools available to fight malaria, but it’s not a panacea. We expect long-lasting insecticide-treated nets (LLINs) and seasonal malaria chemoprevention (SMC)—interventions provided through two of the programs we currently recommend—to continue to be important in the fight against malaria in the near term.2
    • The parts of the WHO news release that we have bolded indicate that RTS,S should be used with existing malaria control interventions:
      • “WHO Director-General Dr Tedros Adhanom Ghebreyesus [said,] ‘Using this vaccine on top of existing tools to prevent malaria could save tens of thousands of young lives each year.'”
      • “WHO recommends that in the context of comprehensive malaria control the RTS,S/AS01 malaria vaccine be used for the prevention of P. falciparum malaria in children living in regions with moderate to high transmission as defined by WHO.”
    • Similarly, Gavi’s news release states: “The vaccine will be a complementary malaria control tool to be added to the core package of WHO-recommended measures for malaria prevention. This includes the routine use of insecticide-treated bed nets, indoor spraying with insecticides, malaria chemoprevention strategies, and the timely use of malaria testing and treatment.”

    jQuery('#footnote_plugin_tooltip_13408_1_2').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_2', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });
  • Simple comparisons of potential costs and effectiveness of RTS,S and SMC suggest that SMC could be more cost-effective (see below). But there are lots of unknowns about RTS,S that could change that.
  • We are actively looking into whether there are promising funding opportunities in this space.
  • So:
    • For the time being, this news does not affect our recommendations to donors. We do not know of a current option for individuals to donate to scale up RTS,S. We continue to believe that LLIN distribution and SMC are highly cost-effective, and some of the best giving opportunities available for donors who want to prevent deaths from malaria today.
    • We aren’t sure whether we’ll recommend funding of RTS,S in the future. That will depend on how cost-effective we estimate particular opportunities to be, which depends on the answers to the open questions listed below.
Simple estimates of cost and effectiveness
  • Cost.​​ SMC costs about $7 per child fully covered per year,3This is the average estimated cost per child in the four countries where we currently recommend funding for SMC. See here in the current version of our cost-effectiveness analysis. jQuery('#footnote_plugin_tooltip_13408_1_3').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_3', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); so it would cost $28 to cover a child for four years. Costs for RTS,S are far less certain. Two studies that seem like reasonable starting points suggest costs per child of between $304See Sauboin et al. 2019, Table 2. The average cost across five countries for administering doses to children is ~$30. jQuery('#footnote_plugin_tooltip_13408_1_4').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_4', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); and $40.5See Winskill et al. 2017, Table 1, row “RTS,S.” jQuery('#footnote_plugin_tooltip_13408_1_5').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_5', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });
  • Effectiveness. Our rough estimate is that RTS,S would avert 36%6“Children were followed up for a median of 48 months (IQR 39–50) and young infants for 38 months (34–41) after dose 1. From month 0 until study end, compared with 9585 episodes of clinical malaria that met the primary case definition in children in the C3C [control] group, 6616 episodes occurred in the R3R [4 doses of RTS,S/AS01] group (VE 36·3%, 95% CI 31·8–40·5)…” RTS,S Clinical Trials Partnership 2015, “Findings” section jQuery('#footnote_plugin_tooltip_13408_1_6').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_6', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); of malaria cases over four years.7We use four years because that’s the time period used in the trials (see the quote in footnote 6 above), and it presents an easy comparison with SMC and other child health programs we support that have annual costs. jQuery('#footnote_plugin_tooltip_13408_1_7').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_7', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); By way of comparison, we estimate that annual SMC would avert 53% of cases over the same time period.8In particular, we assume SMC averts 75% of cases during peak transmission season and that 70% of malaria deaths occur during this period. Because we also assume a 1:1 ratio between cases and deaths averted, this is equivalent to averting ~53% of cases in a year. jQuery('#footnote_plugin_tooltip_13408_1_8').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_8', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });

Taken at face value, these figures could imply that SMC is 1.5 to 2 times more cost-effective than RTS,S. But these naive comparisons aren’t conclusive.9These comparisons are not equivalent to our full cost-effectiveness analyses (CEAs). In complete CEAs, we use country-specific figures instead of averages, try to adjust for internal and external validity, and try to account for the counterfactual funding decisions of all contributors and the value of their funds (which we call leverage and funging adjustments). These adjustments can make decision-relevant differences to our funding recommendations. jQuery('#footnote_plugin_tooltip_13408_1_9').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_9', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });

Open questions

There are many open questions whose answers could have a big impact on the cost-effectiveness of a particular opportunity to support RTS,S. Some questions that seem important to us are:

  • What will it cost to deliver RTS,S? The cost estimates we’ve seen vary widely, and we expect delivery costs to vary from country to country.
  • Will RTS,S be delivered via routine immunization systems or targeted immediately before seasonal malaria transmission? Routine immunization systems might be less costly, but seasonal delivery could increase effectiveness.
  • How will RTS,S be layered with other malaria interventions in new implementation areas? We haven’t thoroughly investigated how the presence of LLINs and SMC in addition to RTS,S affect its efficacy in trial contexts, and we’re unsure how layering would affect the cost-effectiveness of delivering RTS,S in new areas.
In conclusion

We’re excited to have another effective tool in the fight against malaria! We’re working to understand whether there are cost-effective opportunities to support wider-scale implementation of RTS,S. Our research team is also keeping an eye on other potential malaria vaccines and malaria control strategies more generally. In the meantime, we anticipate continuing to recommend funding for LLINs and SMC.

Notes[+]

Notes ↑1 We’ll use “RTS,S” as shorthand in this post. ↑2
  • The parts of the WHO news release that we have bolded indicate that RTS,S should be used with existing malaria control interventions:
    • “WHO Director-General Dr Tedros Adhanom Ghebreyesus [said,] ‘Using this vaccine on top of existing tools to prevent malaria could save tens of thousands of young lives each year.'”
    • “WHO recommends that in the context of comprehensive malaria control the RTS,S/AS01 malaria vaccine be used for the prevention of P. falciparum malaria in children living in regions with moderate to high transmission as defined by WHO.”
  • Similarly, Gavi’s news release states: “The vaccine will be a complementary malaria control tool to be added to the core package of WHO-recommended measures for malaria prevention. This includes the routine use of insecticide-treated bed nets, indoor spraying with insecticides, malaria chemoprevention strategies, and the timely use of malaria testing and treatment.”

↑3 This is the average estimated cost per child in the four countries where we currently recommend funding for SMC. See here in the current version of our cost-effectiveness analysis. ↑4 See Sauboin et al. 2019, Table 2. The average cost across five countries for administering doses to children is ~$30. ↑5 See Winskill et al. 2017, Table 1, row “RTS,S.” ↑6 “Children were followed up for a median of 48 months (IQR 39–50) and young infants for 38 months (34–41) after dose 1. From month 0 until study end, compared with 9585 episodes of clinical malaria that met the primary case definition in children in the C3C [control] group, 6616 episodes occurred in the R3R [4 doses of RTS,S/AS01] group (VE 36·3%, 95% CI 31·8–40·5)…” RTS,S Clinical Trials Partnership 2015, “Findings” section ↑7 We use four years because that’s the time period used in the trials (see the quote in footnote 6 above), and it presents an easy comparison with SMC and other child health programs we support that have annual costs. ↑8 In particular, we assume SMC averts 75% of cases during peak transmission season and that 70% of malaria deaths occur during this period. Because we also assume a 1:1 ratio between cases and deaths averted, this is equivalent to averting ~53% of cases in a year. ↑9 These comparisons are not equivalent to our full cost-effectiveness analyses (CEAs). In complete CEAs, we use country-specific figures instead of averages, try to adjust for internal and external validity, and try to account for the counterfactual funding decisions of all contributors and the value of their funds (which we call leverage and funging adjustments). These adjustments can make decision-relevant differences to our funding recommendations. function footnote_expand_reference_container_13408_1() { jQuery('#footnote_references_container_13408_1').show(); jQuery('#footnote_reference_container_collapse_button_13408_1').text('−'); } function footnote_collapse_reference_container_13408_1() { jQuery('#footnote_references_container_13408_1').hide(); jQuery('#footnote_reference_container_collapse_button_13408_1').text('+'); } function footnote_expand_collapse_reference_container_13408_1() { if (jQuery('#footnote_references_container_13408_1').is(':hidden')) { footnote_expand_reference_container_13408_1(); } else { footnote_collapse_reference_container_13408_1(); } } function footnote_moveToReference_13408_1(p_str_TargetID) { footnote_expand_reference_container_13408_1(); var l_obj_Target = jQuery('#' + p_str_TargetID); if (l_obj_Target.length) { jQuery( 'html, body' ).delay( 0 ); jQuery('html, body').animate({ scrollTop: l_obj_Target.offset().top - window.innerHeight * 0.2 }, 380); } } function footnote_moveToAnchor_13408_1(p_str_TargetID) { footnote_expand_reference_container_13408_1(); var l_obj_Target = jQuery('#' + p_str_TargetID); if (l_obj_Target.length) { jQuery( 'html, body' ).delay( 0 ); jQuery('html, body').animate({ scrollTop: l_obj_Target.offset().top - window.innerHeight * 0.2 }, 380); } }

The post Initial thoughts on malaria vaccine approval appeared first on The GiveWell Blog.

Julie Faller

Initial thoughts on malaria vaccine approval

2 years 6 months ago

The World Health Organization (WHO) recently recommended the widespread use of the malaria vaccine RTS,S/AS01 for children. It provides an additional, effective tool to fight malaria. This is great news!

We've been following this vaccine's development for years and, in the last few months, have been speaking with organizations involved in its development and potential wider rollout.

Our work on RTS,S (and other malaria vaccines) is ongoing, and we might significantly update our views in the near future. But because we've been following its progress, we're sharing some initial thoughts.

Read More

The post Initial thoughts on malaria vaccine approval appeared first on The GiveWell Blog.

Julie Faller

Initial thoughts on malaria vaccine approval

2 years 6 months ago

The World Health Organization (WHO) recently recommended the widespread use of the malaria vaccine RTS,S/AS011We’ll use “RTS,S” as shorthand in this post. jQuery('#footnote_plugin_tooltip_13408_1_1').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_1', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); for children. It provides an additional, effective tool to fight malaria. This is great news!

We’ve been following this vaccine’s development for years and, in the last few months, have been speaking with organizations involved in its development and potential wider rollout.

Our work on RTS,S (and other malaria vaccines) is ongoing, and we might significantly update our views in the near future. But because we’ve been following its progress, we’re sharing some initial thoughts.

In brief
  • This vaccine is a promising addition to the set of tools available to fight malaria, but it’s not a panacea. We expect long-lasting insecticide-treated nets (LLINs) and seasonal malaria chemoprevention (SMC)—interventions provided through two of the programs we currently recommend—to continue to be important in the fight against malaria in the near term.2
    • The parts of the WHO news release that we have bolded indicate that RTS,S should be used with existing malaria control interventions:
      • “WHO Director-General Dr Tedros Adhanom Ghebreyesus [said,] ‘Using this vaccine on top of existing tools to prevent malaria could save tens of thousands of young lives each year.'”
      • “WHO recommends that in the context of comprehensive malaria control the RTS,S/AS01 malaria vaccine be used for the prevention of P. falciparum malaria in children living in regions with moderate to high transmission as defined by WHO.”
    • Similarly, Gavi’s news release states: “The vaccine will be a complementary malaria control tool to be added to the core package of WHO-recommended measures for malaria prevention. This includes the routine use of insecticide-treated bed nets, indoor spraying with insecticides, malaria chemoprevention strategies, and the timely use of malaria testing and treatment.”

    jQuery('#footnote_plugin_tooltip_13408_1_2').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_2', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });
  • Simple comparisons of potential costs and effectiveness of RTS,S and SMC suggest that SMC could be more cost-effective (see below). But there are lots of unknowns about RTS,S that could change that.
  • We are actively looking into whether there are promising funding opportunities in this space.
  • So:
    • For the time being, this news does not affect our recommendations to donors. We do not know of a current option for individuals to donate to scale up RTS,S. We continue to believe that LLIN distribution and SMC are highly cost-effective, and some of the best giving opportunities available for donors who want to prevent deaths from malaria today.
    • We aren’t sure whether we’ll recommend funding of RTS,S in the future. That will depend on how cost-effective we estimate particular opportunities to be, which depends on the answers to the open questions listed below.
Simple estimates of cost and effectiveness
  • Cost.​​ SMC costs about $7 per child fully covered per year,3This is the average estimated cost per child in the four countries where we currently recommend funding for SMC. See here in the current version of our cost-effectiveness analysis. jQuery('#footnote_plugin_tooltip_13408_1_3').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_3', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); so it would cost $28 to cover a child for four years. Costs for RTS,S are far less certain. Two studies that seem like reasonable starting points suggest costs per child of between $304See Sauboin et al. 2019, Table 2. The average cost across five countries for administering doses to children is ~$30. jQuery('#footnote_plugin_tooltip_13408_1_4').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_4', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); and $40.5See Winskill et al. 2017, Table 1, row “RTS,S.” jQuery('#footnote_plugin_tooltip_13408_1_5').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_5', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });
  • Effectiveness. Our rough estimate is that RTS,S would avert 36%6“Children were followed up for a median of 48 months (IQR 39–50) and young infants for 38 months (34–41) after dose 1. From month 0 until study end, compared with 9585 episodes of clinical malaria that met the primary case definition in children in the C3C [control] group, 6616 episodes occurred in the R3R [4 doses of RTS,S/AS01] group (VE 36·3%, 95% CI 31·8–40·5)…” RTS,S Clinical Trials Partnership 2015, “Findings” section jQuery('#footnote_plugin_tooltip_13408_1_6').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_6', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); of malaria cases over four years.7We use four years because that’s the time period used in the trials (see the quote in footnote 6 above), and it presents an easy comparison with SMC and other child health programs we support that have annual costs. jQuery('#footnote_plugin_tooltip_13408_1_7').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_7', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); By way of comparison, we estimate that annual SMC would avert 53% of cases over the same time period.8In particular, we assume SMC averts 75% of cases during peak transmission season and that 70% of malaria deaths occur during this period. Because we also assume a 1:1 ratio between cases and deaths averted, this is equivalent to averting ~53% of cases in a year. jQuery('#footnote_plugin_tooltip_13408_1_8').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_8', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });

Taken at face value, these figures could imply that SMC is 1.5 to 2 times more cost-effective than RTS,S. But these naive comparisons aren’t conclusive.9These comparisons are not equivalent to our full cost-effectiveness analyses (CEAs). In complete CEAs, we use country-specific figures instead of averages, try to adjust for internal and external validity, and try to account for the counterfactual funding decisions of all contributors and the value of their funds (which we call leverage and funging adjustments). These adjustments can make decision-relevant differences to our funding recommendations. jQuery('#footnote_plugin_tooltip_13408_1_9').tooltip({ tip: '#footnote_plugin_tooltip_text_13408_1_9', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });

Open questions

There are many open questions whose answers could have a big impact on the cost-effectiveness of a particular opportunity to support RTS,S. Some questions that seem important to us are:

  • What will it cost to deliver RTS,S? The cost estimates we’ve seen vary widely, and we expect delivery costs to vary from country to country.
  • Will RTS,S be delivered via routine immunization systems or targeted immediately before seasonal malaria transmission? Routine immunization systems might be less costly, but seasonal delivery could increase effectiveness.
  • How will RTS,S be layered with other malaria interventions in new implementation areas? We haven’t thoroughly investigated how the presence of LLINs and SMC in addition to RTS,S affect its efficacy in trial contexts, and we’re unsure how layering would affect the cost-effectiveness of delivering RTS,S in new areas.
In conclusion

We’re excited to have another effective tool in the fight against malaria! We’re working to understand whether there are cost-effective opportunities to support wider-scale implementation of RTS,S. Our research team is also keeping an eye on other potential malaria vaccines and malaria control strategies more generally. In the meantime, we anticipate continuing to recommend funding for LLINs and SMC.

Notes[+]

Notes ↑1 We’ll use “RTS,S” as shorthand in this post. ↑2
  • The parts of the WHO news release that we have bolded indicate that RTS,S should be used with existing malaria control interventions:
    • “WHO Director-General Dr Tedros Adhanom Ghebreyesus [said,] ‘Using this vaccine on top of existing tools to prevent malaria could save tens of thousands of young lives each year.'”
    • “WHO recommends that in the context of comprehensive malaria control the RTS,S/AS01 malaria vaccine be used for the prevention of P. falciparum malaria in children living in regions with moderate to high transmission as defined by WHO.”
  • Similarly, Gavi’s news release states: “The vaccine will be a complementary malaria control tool to be added to the core package of WHO-recommended measures for malaria prevention. This includes the routine use of insecticide-treated bed nets, indoor spraying with insecticides, malaria chemoprevention strategies, and the timely use of malaria testing and treatment.”

↑3 This is the average estimated cost per child in the four countries where we currently recommend funding for SMC. See here in the current version of our cost-effectiveness analysis. ↑4 See Sauboin et al. 2019, Table 2. The average cost across five countries for administering doses to children is ~$30. ↑5 See Winskill et al. 2017, Table 1, row “RTS,S.” ↑6 “Children were followed up for a median of 48 months (IQR 39–50) and young infants for 38 months (34–41) after dose 1. From month 0 until study end, compared with 9585 episodes of clinical malaria that met the primary case definition in children in the C3C [control] group, 6616 episodes occurred in the R3R [4 doses of RTS,S/AS01] group (VE 36·3%, 95% CI 31·8–40·5)…” RTS,S Clinical Trials Partnership 2015, “Findings” section ↑7 We use four years because that’s the time period used in the trials (see the quote in footnote 6 above), and it presents an easy comparison with SMC and other child health programs we support that have annual costs. ↑8 In particular, we assume SMC averts 75% of cases during peak transmission season and that 70% of malaria deaths occur during this period. Because we also assume a 1:1 ratio between cases and deaths averted, this is equivalent to averting ~53% of cases in a year. ↑9 These comparisons are not equivalent to our full cost-effectiveness analyses (CEAs). In complete CEAs, we use country-specific figures instead of averages, try to adjust for internal and external validity, and try to account for the counterfactual funding decisions of all contributors and the value of their funds (which we call leverage and funging adjustments). These adjustments can make decision-relevant differences to our funding recommendations. function footnote_expand_reference_container_13408_1() { jQuery('#footnote_references_container_13408_1').show(); jQuery('#footnote_reference_container_collapse_button_13408_1').text('−'); } function footnote_collapse_reference_container_13408_1() { jQuery('#footnote_references_container_13408_1').hide(); jQuery('#footnote_reference_container_collapse_button_13408_1').text('+'); } function footnote_expand_collapse_reference_container_13408_1() { if (jQuery('#footnote_references_container_13408_1').is(':hidden')) { footnote_expand_reference_container_13408_1(); } else { footnote_collapse_reference_container_13408_1(); } } function footnote_moveToReference_13408_1(p_str_TargetID) { footnote_expand_reference_container_13408_1(); var l_obj_Target = jQuery('#' + p_str_TargetID); if (l_obj_Target.length) { jQuery( 'html, body' ).delay( 0 ); jQuery('html, body').animate({ scrollTop: l_obj_Target.offset().top - window.innerHeight * 0.2 }, 380); } } function footnote_moveToAnchor_13408_1(p_str_TargetID) { footnote_expand_reference_container_13408_1(); var l_obj_Target = jQuery('#' + p_str_TargetID); if (l_obj_Target.length) { jQuery( 'html, body' ).delay( 0 ); jQuery('html, body').animate({ scrollTop: l_obj_Target.offset().top - window.innerHeight * 0.2 }, 380); } }

The post Initial thoughts on malaria vaccine approval appeared first on The GiveWell Blog.

Julie Faller

We’re discontinuing the standout charity designation

2 years 6 months ago

We aim to maximize our impact. That means we focus on directing funds as cost-effectively as we can. Rather than recommending a long list of potential giving options, we focus on finding the organizations that save or improve lives the most per dollar.1We focus on providing a short list of impact-maximizing options that we have intensely vetted. We don’t aim to recommend a long list of potential options for donors. jQuery('#footnote_plugin_tooltip_13382_1_1').tooltip({ tip: '#footnote_plugin_tooltip_text_13382_1_1', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });

Going forward, we will no longer publish a list of standout charities alongside our list of top charities. We think our standout charities are excellent, but we believe donors should support top charities.2For example, in a 2019 blog post on standout charities (“What are standout charities?”), we wrote: “We don’t advise giving to our standout charities over our top charities because we believe that top charities have a greater impact per dollar donated. By definition, top charities have cleared a higher bar of review from GiveWell.” jQuery('#footnote_plugin_tooltip_13382_1_2').tooltip({ tip: '#footnote_plugin_tooltip_text_13382_1_2', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });

Removing standout charities will lead our website to better reflect our recommendations for donors. We hope it will reduce confusion about the difference between top and standout charities and help us direct funding as cost-effectively as possible.

We continue to see the nine standout charities we’ve shared as very strong organizations. This decision doesn’t in any way reflect changes in our evaluation of their programs.

What are standout charities?

We define standout charities as follows:

Standout charities “support programs that may be extremely cost-effective and are evidence-backed. We do not feel as confident in the impact of these organizations as we do in our top charities. However, we have reviewed their work and believe these groups stand out from the vast majority of organizations we have considered in terms of the evidence base for the program they support, their transparency, and their potential cost-effectiveness.”

In other words, we expect that funds directed to top charities are more likely to have a significant impact than those directed to standout charities. We created the standout charity designation to recognize organizations we reviewed that didn’t quite meet our criteria to be top charities, but were very good relative to most. We also hoped the designation would incentivize organizations to engage in our intensive review process.3We discussed this in “What are standout charities?” jQuery('#footnote_plugin_tooltip_13382_1_3').tooltip({ tip: '#footnote_plugin_tooltip_text_13382_1_3', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });

Confusion between top charities and standout charities

However, we’ve realized that it’s confusing to have two different designations for organizations on our website.4In the 2019 blog post referenced above, we wrote: “The standout charity designation, though valuable for the reasons mentioned above, has created communication challenges for us. People who rely on our recommendations to make donations have expressed confusion about how our view of standout charities compares to that of top charities.” jQuery('#footnote_plugin_tooltip_13382_1_4').tooltip({ tip: '#footnote_plugin_tooltip_text_13382_1_4', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); Our recommendation for donors is (and always has been) to give to top charities. Our number-one recommendation for GiveWell donors who want to do as much good as possible is to give to our Maximum Impact Fund, which is allocated to the most cost-effective funding opportunities among our top charities. We don’t allocate the Maximum Impact Fund to standout charities.

Maintaining a list of standout charities for donors is not consistent with our goal of directing funds as cost-effectively as possible.

No changes in our evaluation of standout charities

We made this decision by thinking through how we can communicate more clearly—it wasn’t spurred by any change whatsoever in our views of the standout charities we’ve featured.

Going forward

We think our standout charities are doing great work, even though we’re discontinuing the “standout charity” designation. We’ve recommended that Open Philanthropy make a $100,000 exit grant to each standout charity on our list.

We’re no longer accepting donations for standout charities. We’re contacting donors who have recurring donations set up for our standout charities. If you have an open recurring donation and you haven’t heard from us, please contact us to make sure we accommodate your preferences for cancelling or redirecting your donations.

If you’d like to continue to donate to any of the standout charities, you can do so at the following links. (Note: the links below show tax-deductible options for donors based in the United States. If you’re donating from another country and interested in information on tax-deductibility, please check each organization’s website or contact it directly.)

If you have any questions about your donations, please don’t hesitate to contact us at donations@givewell.org.

Notes[+]

Notes ↑1 We focus on providing a short list of impact-maximizing options that we have intensely vetted. We don’t aim to recommend a long list of potential options for donors. ↑2 For example, in a 2019 blog post on standout charities (“What are standout charities?”), we wrote: “We don’t advise giving to our standout charities over our top charities because we believe that top charities have a greater impact per dollar donated. By definition, top charities have cleared a higher bar of review from GiveWell.” ↑3 We discussed this in “What are standout charities?” ↑4 In the 2019 blog post referenced above, we wrote: “The standout charity designation, though valuable for the reasons mentioned above, has created communication challenges for us. People who rely on our recommendations to make donations have expressed confusion about how our view of standout charities compares to that of top charities.” ↑5 Please note that Precision Development’s mailing address has changed to 1150 Walnut Street, 2nd floor, Waltham, MA 02461. function footnote_expand_reference_container_13382_1() { jQuery('#footnote_references_container_13382_1').show(); jQuery('#footnote_reference_container_collapse_button_13382_1').text('−'); } function footnote_collapse_reference_container_13382_1() { jQuery('#footnote_references_container_13382_1').hide(); jQuery('#footnote_reference_container_collapse_button_13382_1').text('+'); } function footnote_expand_collapse_reference_container_13382_1() { if (jQuery('#footnote_references_container_13382_1').is(':hidden')) { footnote_expand_reference_container_13382_1(); } else { footnote_collapse_reference_container_13382_1(); } } function footnote_moveToReference_13382_1(p_str_TargetID) { footnote_expand_reference_container_13382_1(); var l_obj_Target = jQuery('#' + p_str_TargetID); if (l_obj_Target.length) { jQuery( 'html, body' ).delay( 0 ); jQuery('html, body').animate({ scrollTop: l_obj_Target.offset().top - window.innerHeight * 0.2 }, 380); } } function footnote_moveToAnchor_13382_1(p_str_TargetID) { footnote_expand_reference_container_13382_1(); var l_obj_Target = jQuery('#' + p_str_TargetID); if (l_obj_Target.length) { jQuery( 'html, body' ).delay( 0 ); jQuery('html, body').animate({ scrollTop: l_obj_Target.offset().top - window.innerHeight * 0.2 }, 380); } }

The post We’re discontinuing the standout charity designation appeared first on The GiveWell Blog.

Elie

We’re discontinuing the standout charity designation

2 years 6 months ago

We aim to maximize our impact. That means we focus on directing funds as cost-effectively as we can. Rather than recommending a long list of potential giving options, we focus on finding the organizations that save or improve lives the most per dollar.1We focus on providing a short list of impact-maximizing options that we have intensely vetted. We don’t aim to recommend a long list of potential options for donors. jQuery('#footnote_plugin_tooltip_13382_1_1').tooltip({ tip: '#footnote_plugin_tooltip_text_13382_1_1', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });

Going forward, we will no longer publish a list of standout charities alongside our list of top charities. We think our standout charities are excellent, but we believe donors should support top charities.2For example, in a 2019 blog post on standout charities (“What are standout charities?”), we wrote: “We don’t advise giving to our standout charities over our top charities because we believe that top charities have a greater impact per dollar donated. By definition, top charities have cleared a higher bar of review from GiveWell.” jQuery('#footnote_plugin_tooltip_13382_1_2').tooltip({ tip: '#footnote_plugin_tooltip_text_13382_1_2', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });

Removing standout charities will lead our website to better reflect our recommendations for donors. We hope it will reduce confusion about the difference between top and standout charities and help us direct funding as cost-effectively as possible.

We continue to see the nine standout charities we’ve shared as very strong organizations. This decision doesn’t in any way reflect changes in our evaluation of their programs.

What are standout charities?

We define standout charities as follows:

Standout charities “support programs that may be extremely cost-effective and are evidence-backed. We do not feel as confident in the impact of these organizations as we do in our top charities. However, we have reviewed their work and believe these groups stand out from the vast majority of organizations we have considered in terms of the evidence base for the program they support, their transparency, and their potential cost-effectiveness.”

In other words, we expect that funds directed to top charities are more likely to have a significant impact than those directed to standout charities. We created the standout charity designation to recognize organizations we reviewed that didn’t quite meet our criteria to be top charities, but were very good relative to most. We also hoped the designation would incentivize organizations to engage in our intensive review process.3We discussed this in “What are standout charities?” jQuery('#footnote_plugin_tooltip_13382_1_3').tooltip({ tip: '#footnote_plugin_tooltip_text_13382_1_3', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], });

Confusion between top charities and standout charities

However, we’ve realized that it’s confusing to have two different designations for organizations on our website.4In the 2019 blog post referenced above, we wrote: “The standout charity designation, though valuable for the reasons mentioned above, has created communication challenges for us. People who rely on our recommendations to make donations have expressed confusion about how our view of standout charities compares to that of top charities.” jQuery('#footnote_plugin_tooltip_13382_1_4').tooltip({ tip: '#footnote_plugin_tooltip_text_13382_1_4', tipClass: 'footnote_tooltip', effect: 'fade', predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: 'top right', relative: true, offset: [10, 10], }); Our recommendation for donors is (and always has been) to give to top charities. Our number-one recommendation for GiveWell donors who want to do as much good as possible is to give to our Maximum Impact Fund, which is allocated to the most cost-effective funding opportunities among our top charities. We don’t allocate the Maximum Impact Fund to standout charities.

Maintaining a list of standout charities for donors is not consistent with our goal of directing funds as cost-effectively as possible.

No changes in our evaluation of standout charities

We made this decision by thinking through how we can communicate more clearly—it wasn’t spurred by any change whatsoever in our views of the standout charities we’ve featured.

Going forward

We think our standout charities are doing great work, even though we’re discontinuing the “standout charity” designation. We’ve recommended that Open Philanthropy make a $100,000 exit grant to each standout charity on our list.

We’re no longer accepting donations for standout charities. We’re contacting donors who have recurring donations set up for our standout charities. If you have an open recurring donation and you haven’t heard from us, please contact us to make sure we accommodate your preferences for cancelling or redirecting your donations.

If you’d like to continue to donate to any of the standout charities, you can do so at the following links. (Note: the links below show tax-deductible options for donors based in the United States. If you’re donating from another country and interested in information on tax-deductibility, please check each organization’s website or contact it directly.)

If you have any questions about your donations, please don’t hesitate to contact us at donations@givewell.org.

Notes[+]

Notes ↑1 We focus on providing a short list of impact-maximizing options that we have intensely vetted. We don’t aim to recommend a long list of potential options for donors. ↑2 For example, in a 2019 blog post on standout charities (“What are standout charities?”), we wrote: “We don’t advise giving to our standout charities over our top charities because we believe that top charities have a greater impact per dollar donated. By definition, top charities have cleared a higher bar of review from GiveWell.” ↑3 We discussed this in “What are standout charities?” ↑4 In the 2019 blog post referenced above, we wrote: “The standout charity designation, though valuable for the reasons mentioned above, has created communication challenges for us. People who rely on our recommendations to make donations have expressed confusion about how our view of standout charities compares to that of top charities.” ↑5 Please note that Precision Development’s mailing address has changed to 1150 Walnut Street, 2nd floor, Waltham, MA 02461. function footnote_expand_reference_container_13382_1() { jQuery('#footnote_references_container_13382_1').show(); jQuery('#footnote_reference_container_collapse_button_13382_1').text('−'); } function footnote_collapse_reference_container_13382_1() { jQuery('#footnote_references_container_13382_1').hide(); jQuery('#footnote_reference_container_collapse_button_13382_1').text('+'); } function footnote_expand_collapse_reference_container_13382_1() { if (jQuery('#footnote_references_container_13382_1').is(':hidden')) { footnote_expand_reference_container_13382_1(); } else { footnote_collapse_reference_container_13382_1(); } } function footnote_moveToReference_13382_1(p_str_TargetID) { footnote_expand_reference_container_13382_1(); var l_obj_Target = jQuery('#' + p_str_TargetID); if (l_obj_Target.length) { jQuery( 'html, body' ).delay( 0 ); jQuery('html, body').animate({ scrollTop: l_obj_Target.offset().top - window.innerHeight * 0.2 }, 380); } } function footnote_moveToAnchor_13382_1(p_str_TargetID) { footnote_expand_reference_container_13382_1(); var l_obj_Target = jQuery('#' + p_str_TargetID); if (l_obj_Target.length) { jQuery( 'html, body' ).delay( 0 ); jQuery('html, body').animate({ scrollTop: l_obj_Target.offset().top - window.innerHeight * 0.2 }, 380); } }

The post We’re discontinuing the standout charity designation appeared first on The GiveWell Blog.

Elie

September 2021 open thread

2 years 7 months ago

Our goal with hosting quarterly open threads is to give blog readers an opportunity to publicly raise comments or questions about GiveWell or related topics (in the comments section below). As always, you’re also welcome to email us at info@givewell.org or to request a call with GiveWell staff if you have feedback or questions you’d prefer to discuss privately. We’ll try to respond promptly to questions or comments.

You can view previous open threads here.

The post September 2021 open thread appeared first on The GiveWell Blog.

Catherine Hollander

September 2021 open thread

2 years 7 months ago

Our goal with hosting quarterly open threads is to give blog readers an opportunity to publicly raise comments or questions about GiveWell or related topics (in the comments section below). As always, you’re also welcome to email us at info@givewell.org or to request a call with GiveWell staff if you have feedback or questions you’d prefer to discuss privately. We’ll try to respond promptly to questions or comments.

You can view previous open threads here.

The post September 2021 open thread appeared first on The GiveWell Blog.

Catherine Hollander

June 2021 open thread

2 years 10 months ago

Our goal with hosting quarterly open threads is to give blog readers an opportunity to publicly raise comments or questions about GiveWell or related topics (in the comments section below). As always, you’re also welcome to email us at info@givewell.org or to request a call with GiveWell staff if you have feedback or questions you’d prefer to discuss privately. We’ll try to respond promptly to questions or comments.

You can view previous open threads here.

The post June 2021 open thread appeared first on The GiveWell Blog.

Catherine Hollander

June 2021 open thread

2 years 10 months ago

Our goal with hosting quarterly open threads is to give blog readers an opportunity to publicly raise comments or questions about GiveWell or related topics (in the comments section below). As always, you’re also welcome to email us at info@givewell.org or to request a call with GiveWell staff if you have feedback or questions you’d prefer to discuss privately. We’ll try to respond promptly to questions or comments.

You can view previous open threads here.

The post June 2021 open thread appeared first on The GiveWell Blog.

Catherine Hollander